Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.70 |
| ▸ | NPC1 | O15118 | 5/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.70 |
| ▸ | RAB9A | P51151 | 4/20 | 0.70 |
| ▸ | GAA | P10253 | 1/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.70 |
| ▸ | MEN1 | O00255 | 2/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.70 |
| ▸ | TSHR | P16473 | 1/20 | 0.70 |
| ▸ | TP53 | P04637 | 5/20 | 0.66 |
| ▸ | HPGD | P15428 | 4/20 | 0.66 |
| ▸ | BACE1 | P56817 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.58 |
| ▸ | THRB | P10828 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3224263 | 0.86 | SMN1; SMN2 (0.67) | MAPTKDM4EALDH1A1NPC1SMN1; SMN2 | |
| SCHEMBL3226406 | 0.85 | NPC1 (0.63) | MAPTKDM4EALDH1A1NPC1SMN1; SMN2 | |
| SCHEMBL27759195 | 0.83 | KDM4E (1.00) | MAPTKDM4EALDH1A1NPC1SMN1; SMN2 | |
| SCHEMBL3221640 | 0.81 | TP53 (0.65) | MAPTKDM4EALDH1A1NPC1SMN1; SMN2 | |
| SCHEMBL27759222 | 0.80 | NPC1 (0.76) | MAPTKDM4EALDH1A1NPC1SMN1; SMN2 | |
| SCHEMBL3227164 | 0.80 | NPC1 (0.84) | MAPTKDM4EALDH1A1NPC1SMN1; SMN2 | |
| SCHEMBL3220399 | 0.77 | NPC1 (0.81) | MAPTKDM4EALDH1A1NPC1SMN1; SMN2 | |
| SCHEMBL3210146 | 0.77 | NPC1 (0.74) | MAPTKDM4EALDH1A1NPC1SMN1; SMN2 | |
| SCHEMBL24457961 | 0.77 | MAPT (0.62) | MAPTKDM4EALDH1A1NPC1SMN1; SMN2 | |
| SCHEMBL3226787 | 0.76 | MAPT (0.82) | MAPTKDM4EALDH1A1NPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100168072-A1 | Drug Combinations for the Treatment of Duchenne Muscular Dystrophy | BIOMARIN IGA LIMITED | 2010-07-01 | — | — | US | disclosed |
| US-20100048660-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | BIOMARIN IGA LIMITED (BS) | 2010-02-25 | — | — | US | disclosed |
| CN-101420952-A | Treatment of duchenne muscular dystrophy | SUMMIT CORP PLC (GB) | 2009-04-29 | — | — | CN | disclosed |
| EP-1986643-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | Summit Corporation Plc (GB) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007091107-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2007-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048660-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SMN1; SMN2, CPT1B, GYS1 | MAPT 4772/4885KDM4E 3777/4885ALDH1A1 516/4885 |
| US-20100168072-A1 | Drug Combinations for the Treatment of Duchenne Muscular Dystrophy | CPT1B, PYGM, MTPN | MAPT 2870/4885KDM4E 3419/4885ALDH1A1 1092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.